GlassScriptPhysician profile
Kevin Chang
NPI 1649219452
$22,063.38
in general payments reported to CMS, 2019-2025
70 companies · $5,040 in 2025
The $5,040 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,716 · 2020: $930 · 2021: $416 · 2022: $2,514 · 2023: $3,698 · 2024: $4,749 · 2025: $5,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $2,299 · Education: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,694.15 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $494.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,297.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,812.77 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $1,363.06 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,196.82 | 2019-2025 | Darzalex, Talvey, Carvykti |
| Astellas Pharma US INC | $1,007.97 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Pfizer INC. | $849.67 | 2019-2025 | |
| Incyte Corporation | $846.08 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Genzyme Corporation | $773.22 | 2019-2024 | |
| Abbvie INC. | $764.95 | 2019-2025 | Venclexta |
| Celgene Corporation | $715.44 | 2019-2025 | Reblozyl |
| Amgen INC. | $666.23 | 2019-2024 | Evenity, Prolia, Kyprolis |
| Genentech USA, INC. | $593.18 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| Takeda Pharmaceuticals U.S.A., INC. | $508.70 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $499.61 | 2019-2025 | Opdualag, Opdivo |
| Emd Serono, INC. | $471.13 | 2022-2025 | Tepmetko, Bavencio |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.